A detailed history of Qube Research & Technologies LTD transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 690,918 shares of FOLD stock, worth $6.23 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
690,918
Previous 60,990 1032.84%
Holding current value
$6.23 Million
Previous $605,000 1119.67%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.55 - $12.09 $6.02 Million - $7.62 Million
629,928 Added 1032.84%
690,918 $7.38 Million
Q2 2024

Aug 14, 2024

SELL
$9.04 - $11.75 $4.48 Million - $5.82 Million
-495,373 Reduced 89.04%
60,990 $605,000
Q1 2024

May 14, 2024

BUY
$11.43 - $14.24 $6.36 Million - $7.92 Million
556,363 New
556,363 $6.55 Million
Q1 2023

May 15, 2023

BUY
$10.91 - $13.54 $1.53 Million - $1.89 Million
139,829 Added 217.5%
204,119 $2.26 Million
Q4 2022

Feb 14, 2023

SELL
$9.89 - $12.7 $57,154 - $73,393
-5,779 Reduced 8.25%
64,290 $784,000
Q3 2022

Nov 14, 2022

BUY
$9.82 - $12.75 $688,077 - $893,379
70,069 New
70,069 $732,000
Q4 2021

Feb 01, 2022

SELL
$9.82 - $12.44 $349,277 - $442,465
-35,568 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$8.74 - $11.84 $184,580 - $250,048
21,119 Added 146.16%
35,568 $340,000
Q2 2021

Aug 13, 2021

SELL
$8.71 - $10.72 $101,819 - $125,316
-11,690 Reduced 44.72%
14,449 $139,000
Q1 2021

May 14, 2021

BUY
$9.2 - $23.86 $240,478 - $623,676
26,139 New
26,139 $258,000
Q4 2020

Feb 16, 2021

SELL
$13.47 - $24.89 $412,963 - $763,077
-30,658 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$12.89 - $15.89 $262,234 - $323,266
20,344 Added 197.25%
30,658 $433,000
Q2 2020

Aug 14, 2020

BUY
$8.86 - $15.69 $91,382 - $161,826
10,314 New
10,314 $156,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.53B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.